The Access Problem That Regulation Is Solving
The global hearing health market has been characterised for decades by a significant gap between the prevalence of hearing loss — affecting approximately 430 million people worldwide according to the World Health Organization, with the great majority in low and middle-income countries — and the rate of hearing aid adoption, estimated at below 20 percent of those who could benefit from amplification. The factors contributing to this treatment gap are well documented: the high cost of prescription hearing aids, whose average retail price in the United States has been approximately $4,700 per pair and whose price reflects the professional dispensing model in which audiologists and hearing instrument specialists provide fitting, adjustment, and ongoing service that is bundled into the product price; the social stigma associated with visible hearing aids that causes many people with hearing loss to defer adoption beyond the point where their communication difficulties have significantly affected quality of life; and the inconvenience of the clinical care pathway, which requires multiple appointments with hearing professionals for evaluation, selection, fitting, and follow-up that create time and access barriers in addition to financial ones. The consequence of these barriers is a market whose penetration rate has remained stubbornly low despite the clinical availability of effective hearing aids for decades and despite the growing elderly population whose prevalence of age-related hearing loss is the primary driver of addressable market size.
The regulatory change that is most directly addressing the access problem is the US Food and Drug Administration's 2022 rule establishing a new over-the-counter category for hearing aids — allowing hearing aids to be sold directly to consumers without a prescription or professional fitting for adults with mild to moderate hearing loss. The OTC hearing aid rule, implementing the Over-the-Counter Hearing Aid Act of 2017, ended the prescription requirement that had maintained the professional dispensing model as the only legal pathway for hearing aid access in the United States and created the regulatory framework for consumer electronics companies, technology startups, and established hearing aid manufacturers to sell hearing aids directly to consumers at price points that can reach below $300 compared to the thousands of dollars of traditional prescription hearing aids.
The OTC Market's Commercial Development
The commercial market for OTC hearing aids has developed rapidly since the FDA rule took effect in October 2022, with products from Sony, Jabra, Philips (through its hearing health brand), Lexie, and a growing range of startups entering retail channels including Amazon, Best Buy, CVS, and Walmart at price points that represent a fundamental commercial disruption to the traditional hearing aid market. The technology platforms these products use — smartphone-connected hearing aids whose fitting is performed through guided self-fitting apps rather than audiologist programming — represent a genuinely different product category from prescription hearing aids in their user experience, their technical architecture, and their commercial model. The self-fitting app guides the user through a hearing assessment, applies a personalised sound profile based on the assessment results, and provides a degree of personalisation that, while less precise than professional audiologist fitting, is sufficient for many users with mild to moderate hearing loss to achieve meaningful benefit from amplification.
The commercial performance of the OTC hearing aid market in its first two years has been mixed relative to the optimistic projections that accompanied the FDA rule. Consumer awareness of OTC hearing aids remains limited, the category's placement in retail electronics rather than healthcare settings creates discovery challenges for consumers who associate hearing care with clinical rather than retail environments, and the self-fitting process — while dramatically simpler than the professional fitting pathway — still requires a level of engagement and persistence that some consumers with hearing loss find challenging. The OTC market's growth is proceeding, but the transformation of the hearing aid market is occurring more gradually than the most optimistic projections suggested, with the traditional professional dispensing channel retaining a larger market share than OTC advocates anticipated in the immediate post-rule period.
Teleaudiology and Digital Fitting: The Clinical Channel's Response
The professional audiology channel's response to the OTC disruption has not been passive acceptance of market displacement but active investment in digital technology that reduces the cost and improves the convenience of the professional fitting pathway — addressing the access barriers of traditional hearing care without abandoning the clinical expertise that professional audiologists provide. Teleaudiology — the remote delivery of hearing assessment, hearing aid fitting, and follow-up care through video consultation and cloud-connected hearing aid programming — is growing as a commercial service offering that extends clinical hearing care to patients who cannot easily attend in-person appointments due to mobility limitations, geographic distance from audiology practices, or the time constraints of managing multiple healthcare and personal commitments.
The remote fine-tuning capability of modern prescription hearing aids — all major manufacturers now offer cloud-connected hearing aids that can be remotely adjusted by an audiologist accessing the aid's fitting parameters through a secure cloud platform — is reducing the number of in-person appointments required for successful hearing aid fitting and creating the hybrid clinical model in which the initial evaluation and fitting is performed in person but ongoing adjustment and optimisation is delivered remotely. The commercial economics of teleaudiology for audiology practices are compelling — extending the practice's geographic reach, improving audiologist productivity by serving more patients per day without physical appointment slots, and improving patient adherence to hearing aid use by making the adjustment process less demanding. The established hearing aid manufacturers — Phonak, Signia, ReSound, Oticon, and Starkey — are investing in teleaudiology platform capabilities and remote programming infrastructure as competitive differentiators that maintain the clinical channel's relevance in a market where the OTC alternative is reducing the barriers to non-clinical hearing aid access.
Hearables and the Convergence With Consumer Audio
The technological convergence between premium consumer audio products — particularly true wireless earbuds from Apple, Samsung, and other consumer electronics leaders — and hearing aid functionality is creating a new market category whose commercial development blurs the boundary between consumer audio and hearing health. Apple's AirPods Pro, whose Transparency Mode and recently introduced Hearing Aid feature (available for users with mild to moderate hearing loss) represent the integration of hearing aid-like sound amplification and personalisation into a premium consumer audio product that does not carry the stigma or the clinical connotations of a hearing aid. The commercial implications of this convergence are significant for the traditional hearing health market — Apple's existing AirPods user base is vastly larger than the hearing aid market, and the accessibility of hearing aid functionality within a consumer audio product that users already own and use daily could substantially accelerate adoption of hearing assistance by the large population with mild hearing loss who have deferred engagement with traditional hearing care pathways.